US Election 2016
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
With an all-Republican House, Senate and administration lined up to lead the government following the 2016 elections, the path is clear for passage of a set of FDA reforms to ease device approvals embedded in a combined House 'Cures' and Senate medical innovation package. It could even happen over the upcoming lame-duck session, before the new administration and Congress take over. But controversy around price-gouging by drug firms still could stymie quick Cures bill passage, an industry attorney predicts. Meanwhile, medtech industry groups plan to seize on the Trump victory as a means to achieve permanent device tax repeal.
Latest From US Election 2016 & Medical Device
In this free podcast, In Vivo asks AdvaMed government affairs director JC Scott what the medical technology industry hopes for, expects, and fears from the new Republican US president.
BD CEO Vince Forlenza just finished his two-year term as board chairman of AdvaMed. For the most part, his successor will face the same priorities he did during his tenure: repealing the 2.3 percent medical device excise tax and reauthorizing device user fees. Forlenza spoke with Medtech Insight in this podcast interview.
It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.
Seema Verma, President Trump's nominee to lead the Medicare agency, was approved by the Senate Finance Committee March 2 on a narrow 13-12 vote; her confirmation will now be taken up by the full Senate. Questions remain about Verma's viewpoints related to replacement of the Affordable Care Act and on promoting alternative Medicare value-based payment models.
Seema Verma, President Trump’s pick to run the US Medicare agency, told the Senate Finance Committee that rural areas should not have to comply with CMS’ medical supplies competitive-bidding program if it is not a good fit. Verma was also questioned on changes she might make to the Affordable Care Act and the Medicare program, but did not offer many specifics.
Even though the executive order that requires regulatory offsets may only have limited application to the agency, industry experts warn that it still could prove to be unwieldly to implement.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.